Post-stroke treatment targets avoidance of recurrent stroke or other complications of the brain illness and on maximizing recovery with rehabilitation. ‘The results of this study are important because they imply early administration of an adjunctive medication, an antidepressant, might have an effect on improving outcomes independent of the medication’s activities on mood,’ stated Harold Adams, M.D., UI professor of neurology and a scholarly study co-author. ‘If future studies confirm our observation concerning the use of antidepressant medicines as an ancillary therapy directed at people with stroke, including those without melancholy, the public health impact could possibly be large.’ Related StoriesScreening for asymptomatic atrial fibrillation could decrease risk of stroke, premature deathPacemakers can identify AF and enable initiation of anticoagulation for stroke preventionMeta-evaluation backs thrombectomy over standard stroke careThe study suggests that the antidepressant medication is doing something, independent of treating depression, that increases physical recovery from stroke.It’s a huge honor and privilege because of what the award represents, said Shane, who also received the pharmacist society’s award for distinguished leadership in 2005. The recognition from my peers means a lot to me. Shane started her career at Cedars-Sinai in 1977 as an intern pharmacist after making her doctorate from USC’s College of Pharmacy. She became a clinical pharmacist in pediatrics and rose to be director of pharmacy solutions in 1988 steadily. Simultaneously, she ascended the ranks of academia, beginning as an assistant clinical professor at USC and later earning an appointment as associate dean of medical pharmacy at UC San Francisco’s College of Pharmacy.